Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 13/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6408594 | 0.99 | SLC6A4 (0.41) | SLC6A4SLC6A3CCR5UTS2RNPC1 | |
| SCHEMBL6409448 | 0.99 | SLC6A4 (0.42) | SLC6A4SLC6A3CCR5UTS2RNPC1 | |
| Hydrochloric Acid SCHEMBL6414819 | 0.98 | SLC6A4 (0.41) | SLC6A4SLC6A3CCR5UTS2RNPC1 | |
| SCHEMBL6410602 | 0.96 | CCR5 (0.44) | SLC6A4SLC6A3CCR5UTS2RSIGMAR1 | |
| Hydrochloric Acid SCHEMBL6414464 | 0.95 | CCR5 (0.43) | SLC6A4SLC6A3CCR5UTS2RSIGMAR1 | |
| SCHEMBL6410269 | 0.90 | CCR5 (0.51) | SLC6A4SLC6A3CCR5 | |
| Hydrochloric Acid SCHEMBL5252103 | 0.89 | CCR5 (0.50) | SLC6A4SLC6A3CCR5 | |
| SCHEMBL6416649 | 0.89 | CCR2 (0.47) | CCR5 | |
| SCHEMBL6414955 | 0.89 | CCR5 (0.51) | SLC6A4SLC6A3CCR5SIGMAR1 | |
| SCHEMBL5251436 | 0.89 | CCR5 (0.51) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | SLC6A4 1751/4885SLC6A3 1200/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.